Effectiveness and Community Acceptance of Extending Seasonal Malaria Chemoprevention to Children 5 to 14 Years of Age in Dangassa, Mali

Drissa Konaté, Sory Ibrahim Diawara, Bourama Keita, Nafomon Sogoba, Mahamadou Fayiçal, Agnès Guindo, Sibe Thiam, Sékou Fantamady Traoré, Jeffrey G Shaffer, Seydou Doumbia, Mahamadou Diakité, Drissa Konaté, Sory Ibrahim Diawara, Bourama Keita, Nafomon Sogoba, Mahamadou Fayiçal, Agnès Guindo, Sibe Thiam, Sékou Fantamady Traoré, Jeffrey G Shaffer, Seydou Doumbia, Mahamadou Diakité

Abstract

Seasonal malaria chemoprevention (SMC) was adopted in Mali in 2012 for preventing malaria in children younger than 5 years. Although this strategy has been highly effective in reducing childhood malaria, an uptick in malaria occurrence has occurred in children 5 to 15 years of age. This study aimed to investigate the feasibility of providing SMC to older children. A cohort of 350 children age 5 to 14 years were monitored during the 2019 transmission season in Dangassa, Mali. The intervention group received five monthly rounds of sulfadoxine-pyrimethamine plus amodiaquine, whereas the control group consisted of untreated children. Community acceptance for extending SMC was assessed during the final round. Logistic regression models were applied to compare the risk of Plasmodium falciparum malaria infection, anemia, and fever between the intervention and control groups. Kaplan-Meier survival analyses were used to compare the time to P. falciparum parasitemia infection between the groups. The community acceptance rate was 96.5% (139 of 144). Significant declines were observed in the prevalence of P. falciparum parasitemia (adjusted odds ratio, 0.22; 95% CI, 0.11-0.42) and anemia (adjusted odds ratio, 0.15; 95% CI, 0.07-0.28) in the intervention group compared with the control group. The cumulative incidence of P. falciparum infections was significantly greater (75.4%, 104 of 138) in the control group compared with the intervention group (40.7%, 61 of 143, P = 0.001). This study reveals that expanding SMC to older children is likely feasible, has high community acceptance, and is in reducing uncomplicated malaria and anemia in older children.

Trial registration: ClinicalTrials.gov NCT04149106.

Figures

Figure 1.
Figure 1.
Monthly follow-up of children during seasonal malaria chemoprevention, Dangassa, Mali.
Figure 2.
Figure 2.
Community acceptance of seasonal malaria chemoprevention, Dangassa, Mali. This figure appears in color at www.ajtmh.org.
Figure 3.
Figure 3.
Monthly prevalence of Plasmodium falciparum parasitemia. This figure appears in color at www.ajtmh.org.
Figure 4.
Figure 4.
Time to Plasmodium falciparum parasitemia infection. This figure appears in color at www.ajtmh.org.

References

    1. INSTAT/CPS/SS-DS-PF/ICF , 2019. Enquête Démographique et de Santé au Mali 2018. Available at: . Accessed April 16, 2020.
    1. World Health Organization , 2018. World Malaria Report 2018. License: CC BY-NC-SA 3.0 IGO. Geneva, Switzerland: WHO.
    1. World Health Organization , 2012. World Malaria Report 2012. Available at: . Accessed November 18, 2020.
    1. Medecins Sans Frontieres , 2013. Chimioprevention du Paludisme Saisnnier, district de Koutiala, Région Sikasso, Mali. Available at: . Accessed October 11, 2021.
    1. Barry A et al. 2018. Optimal mode for delivery of seasonal malaria chemoprevention in Ouelessebougou, Mali: a cluster randomized trial. PLoS One 13: e0193296.
    1. Cisse B et al. 2016. Effectiveness of seasonal malaria chemoprevention in children under ten years of age in Senegal: a stepped-wedge cluster-randomised trial. PLoS Med 13: e1002175.
    1. Druetz T et al. 2017. Effect of interrupting free healthcare for children: drawing lessons at the critical moment of national scale-up in Burkina Faso. Soc Sci Med 185: 46–53.
    1. Partnership A-S, 2020. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet 396: 1829–1840.
    1. Noor AM et al. 2015. Sub-national targeting of seasonal malaria chemoprevention in the Sahelian countries of the Nouakchott Initiative. PLoS One 10: e0136919.
    1. Meremikwu MM et al. 2012. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst Rev CD003756.
    1. Konate AT et al. 2011. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med 8: e1000408.
    1. Grobusch MP et al. 2009. No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon. J Infect Dis 200: 1658–1661.
    1. Ba EH et al. 2018. Implementation, coverage and equity of large-scale door-to-door delivery of seasonal malaria chemoprevention (SMC) to children under 10 in Senegal. Sci Rep 8: 5489.
    1. Okiro EA et al. 2009. Age patterns of severe paediatric malaria and their relationship to Plasmodium falciparum transmission intensity. Malar J 8: 4.
    1. Coulibaly D et al. 2021. A decline and age shift in malaria incidence in rural Mali following implementation of seasonal malaria chemoprevention and indoor residual spraying. Am J Trop Med Hyg 104: 1342–1347.
    1. Nkumama IN O’Meara WP Osier FHA , 2017. Changes in malaria epidemiology in Africa and new challenges for elimination. Trends Parasitol 33: 128–140.
    1. Konate D et al. 2020. Effect of routine seasonal malaria chemoprevention on malaria trends in children under 5 years in Dangassa, Mali. Malar J 19: 137.
    1. Diawara F et al. 2017. Measuring the impact of seasonal malaria chemoprevention as part of routine malaria control in Kita, Mali. Malar J 16: 325.
    1. Ambe JP et al. 2020. Impacts of seasonal malaria chemoprevention on malaria burden among under five-year-old children in Borno State, Nigeria. J Trop Med 2020: 9372457.
    1. Thera MA et al. 2018. School-aged children based seasonal malaria chemoprevention using artesunate-amodiaquine in Mali. Parasite Epidemiol Control 3: 96–105.
    1. Garg S et al. 2020. Coverage of community case management for malaria through CHWs: a quantitative assessment using primary household surveys of high-burden areas in Chhattisgarh state of India. Malar J 19: 213.
    1. Issiaka D et al. 2020. Impact of seasonal malaria chemoprevention on hospital admissions and mortality in children under 5 years of age in Ouelessebougou, Mali. Malar J 19: 103.
    1. Dicko A et al. 2011. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med 8: e1000407.
    1. Ndiaye JLA et al. 2019. Seasonal malaria chemoprevention combined with community case management of malaria in children under 10 years of age, over 5 months, in south-east Senegal: a cluster-randomised trial. PLoS Med 16: e1002762.
    1. Sylla K. et al., 2017. Effect of seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) on the acquisition of anti-AMA1 and anti-MSP1_42 antibodies among children under 10 years living in the southern part of Senegal (Velingara). Malaria Control & Elimination, 06.
    1. Tagbor H et al. 2016. Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial. Trop Med Int Health 21: 224–235.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere